BioCentury
ARTICLE | Finance

Normalizing oxygen

NormOxys garners a $17.5M B round for oxygen normalization in cancer, CHF

May 24, 2010 7:00 AM UTC

Investors are hoping to get the lead candidate for NormOxys Inc. through Phase IIa trials in two indications with $17.5 million from a series B1 round, Jerry Karabelas of Care Capital told Ebb & Flow.

The company's oxyren small molecules enhance hemoglobin's ability to release oxygen. They are expected to treat and modify diseases by normalizing oxygen pressure without the risk of hyperoxygen-ation (see BioCentury, Dec. 7, 2009)...